Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Epidemiology of metabolic dysfunction-associated steatotic liver disease

Zobair M. Younossi, Markos Kalligeros, Linda Henry

Clin Mol Hepatol. 2025;31(Suppl):S32-S50. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0431

View: 15558 Download: 1,995 Web of Science: 68 Crossref: 71

Original Article

Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments

Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian

Clin Mol Hepatol. 2025;31(1):179-195. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0359

View: 1964 Download: 167 Web of Science: 2 Crossref: 2

Letter to the Editor

Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):962-964. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0264

View: 2129 Download: 110 Web of Science: 2 Crossref: 4

Original Article

Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George

Clin Mol Hepatol. 2024;30(3):436-448. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0109

View: 7862 Download: 348 Web of Science: 20 Crossref: 19

Letter to the Editor

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 3556 Download: 149 Web of Science: 11 Crossref: 11

Correspondence

Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2024;30(1):126-128. Published online November 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0500

View: 4279 Download: 54

Review

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra

Clin Mol Hepatol. 2023;29(Suppl):S286-S301. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0392

View: 8576 Download: 290 Web of Science: 26 Crossref: 32

Special Review

Waiting for the changes after the adoption of steatotic liver disease

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(4):844-850. Published online September 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0291

View: 4271 Download: 188 Web of Science: 37 Crossref: 42

Editorial

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology

Eileen Laurel Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):371-373. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0086

View: 4201 Download: 141 Web of Science: 9 Crossref: 8

Review

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Shang-Chin Huang, Chun-Jen Liu

Clin Mol Hepatol. 2023;29(2):320-331. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0422

View: 9129 Download: 483 Web of Science: 45 Crossref: 51

Original Article

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):841-850. Published online September 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0239

View: 11328 Download: 328 Web of Science: 153 Crossref: 162

Editorial

Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2022;28(4):802-805. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0249

View: 4082 Download: 89 Web of Science: 4 Crossref: 5

Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults

Byoung Seok Ye

Clin Mol Hepatol. 2022;28(3):481-482. Published online May 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0097

View: 3853 Download: 87 Web of Science: 1 Crossref: 2

Original Article

Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study

Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae

Clin Mol Hepatol. 2022;28(2):196-206. Published online January 13, 2022

DOI: https://doi.org/10.3350/cmh.2021.0371

View: 7473 Download: 225 Web of Science: 22 Crossref: 23

Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome

Han Ah Lee, Jihwan Lim, Hyung Joon Joo, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Do-Sun Lim, Kwan Soo Byun, Yeon Seok Seo

Clin Mol Hepatol. 2021;27(3):463-473. Published online February 15, 2021

DOI: https://doi.org/10.3350/cmh.2020.0351

View: 6942 Download: 181 Web of Science: 4 Crossref: 5

Review

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee, On behalf of Korean NAFLD Study Group

Clin Mol Hepatol. 2021;27(2):257-269. Published online March 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0067

View: 10571 Download: 449 Web of Science: 71 Crossref: 74

Editorial

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try

Tian-Yi Ren, Xiao-Yan Li, Jian-Gao Fan

Clin Mol Hepatol. 2021;27(1):83-86. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0298

View: 6231 Download: 172 Web of Science: 1 Crossref: 1

Review

Application of transient elastography in nonalcoholic fatty liver disease

Xinrong Zhang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2020;26(2):128-141. Published online November 8, 2019

DOI: https://doi.org/10.3350/cmh.2019.0001n

View: 17953 Download: 586 Web of Science: 83 Crossref: 89

Original Article

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B

Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang

Clin Mol Hepatol. 2019;25(1):52-64. Published online October 23, 2018

DOI: https://doi.org/10.3350/cmh.2018.0040

View: 10118 Download: 365 Web of Science: 87 Crossref: 84

Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study

Gi Hyun Kim, Jung Wha Chung, Jong Ho Lee, Kyeong Sam Ok, Eun Sun Jang, Jaihwan Kim, Cheol Min Shin, Young Soo Park, Jin-Hyeok Hwang, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee, Jin-Wook Kim

Clin Mol Hepatol. 2015;21(4):379-386. Published online December 24, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.4.379

View: 13616 Download: 183 Web of Science: 17 Crossref: 14

Association of serum alanine aminotransferase and γ-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease

Hyo Jeong Oh, Tae Hyeon Kim, Young Woo Sohn, Yong Sung Kim, Yong Reol Oh, Eun Young Cho, So Yeon Shim, Sae Ron Shin, A Lum Han, Seok Jin Yoon, Haak Cheoul Kim

Clin Mol Hepatol. 2011;17(1):27-36. Published online March 21, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.1.27

View: 11192 Download: 90 Crossref: 54

Editorial

Liver function tests as indicators of metabolic syndrome

Han Chu Lee

Clin Mol Hepatol. 2011;17(1):9-11. Published online March 21, 2011

DOI: https://doi.org/10.3350/kjhep.2011.17.1.9

View: 6536 Download: 50 Crossref: 4

3

Nonalcoholic fatty Liver disease as a risk factor of cardiovascular disease; Relation of non-alcoholic fatty Liver disease to carotid atherosclerosis

Su-Yeon Choi, M.D., Donghee Kim, M.D., Jin Hwa Kang, M.D. Min Jung Park, M.D., Young Sun Kim, M.D., Seon Hee Lim, M.D., Chung Hyeon Kim, M.D., Hyo-Suk Lee, M.D.

Clin Mol Hepatol. 2008;14(1):77-88. Published online March 20, 2008

DOI: https://doi.org/10.3350/kjhep.2008.14.1.77

View: 7276 Download: 131 Crossref: 30

1

Nonalcoholic fatty Liver disease as a risk factor of cardiovascular disease

Moon Young Kim , Soon Koo Baik

Clin Mol Hepatol. 2008;14(1):1-3. Published online March 20, 2008

DOI: https://doi.org/10.3350/kjhep.2008.14.1.1

View: 5477 Download: 67 Crossref: 2

5

Nonalcoholic Steatohepatitis

So-Young Jin

Clin Mol Hepatol. 2006;12(3):455-459. Published online January 1, 2000

View: 2914 Download: 21

3

The Prevalence of Metabolic Syndrome in Patients with Nonalcoholic Fatty Liver Disease

Ki Won Moon, M.D., Joung Muk Leem, M.D., Sang Seok Bae, M.D., Ki Man Lee, M.D., Seok Hyung Kim, M.D.*, Hee Bok Chae, M.D., Seon Mee Park, M.D. and Sei Jin Youn, M.D.

Clin Mol Hepatol. 2004;10(3):197-206. Published online January 1, 1970

View: 3525 Download: 59

Letter to the Editor

What is new in the 2024 Chinese guidelines for fatty liver disease?

Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan

Received December 27, 2024 Accepted January 18, 2025

DOI: https://doi.org/10.3350/cmh.2024.1165 [Accepted]

View: 561 Download: 56

1 |

Viewed By 11970	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7500	MAFLD: How is it different from NAFLD?
Viewed By 6574	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5752	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 5380	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 355	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 331	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 223	MAFLD: How is it different from NAFLD?
Cited By 114	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 110	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search